Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

10.1186/s12885-018-5110-2

Saved in:

Bibliographic Details
Main Authors:	Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel SW, Lim, Darren Wan-Teck
Other Authors:	DEAN'S OFFICE (DUKE-NUS MEDICAL SCHOOL)
Format:	Article
Language:	English
Published:	BMC 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology EGFR mutation NSCLC Metastatic Afatinib Brain metastases Dose CELL LUNG-CANCER RECEPTOR GENE-MUTATIONS INTERNATIONAL-ASSOCIATION EFFICACY ADENOCARCINOMA GEFITINIB ERLOTINIB SAFETY COMMON
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/218617
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Similar Items

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
by: Park, Keunchil, et al.
Published: (2022)

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
by: Chang, Gee-Chen, et al.
Published: (2022)

Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china
by: You, R., et al.
Published: (2021)

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR plus non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance
by: Ma, Jun, et al.
Published: (2024)

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
by: Tan, Eng-Huat, et al.
Published: (2022)

Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian Lung adenocarcinomas
by: Toh, C.-K., et al.
Published: (2014)

Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure
by: Saw, Stephanie PL, et al.
Published: (2024)

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial
by: Schuler, M, et al.
Published: (2024)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases (vol 18, 1198, 2018)
by: Tan, Wan-Ling, et al.
Published: (2022)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
by: Yeo, W.-L., et al.
Published: (2011)

Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma
by: Lee, S.-C., et al.
Published: (2012)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
by: Kannan, S, et al.
Published: (2020)

Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
by: Chaichana Chantharakhit
Published: (2019)

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)
by: Lim, E.H., et al.
Published: (2011)

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)
by: Lim, E.H., et al.
Published: (2014)

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
by: Chua, Khi Pin, et al.
Published: (2024)

KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma
by: Pang, N.K.B., et al.
Published: (2014)

EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
by: Assiddiq, B.F., et al.
Published: (2014)

Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis
by: Lee, Chia Ching, et al.
Published: (2022)

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach
by: Salto-Tellez, M., et al.
Published: (2014)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
by: Wong, A.S., et al.
Published: (2014)

CLINICAL AND FUNCTIONAL SIGNIFICANCE OF CD151 IN WILDTYPE EGRF NSCLC
by: WONG HUEE PING AMANDA
Published: (2020)

An alternative approach to determining therapeutic choices in advanced non-small cell lung carcinoma (NSCLC): Maximizing the diagnostic procedure and the use of low-volume lung biopsies
by: Lim, E.H., et al.
Published: (2011)

RUNX3 downregulation in human lung adenocarcinoma is independent of p53, EGFR or KRAS status
by: Omar, M.F.M., et al.
Published: (2014)

EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction
by: Kumarakulasinghe, N.B, et al.
Published: (2020)

Blocking aerobic glycolysis by targeting pyruvate dehydrogenase kinase in combination with egfr tki and ionizing radiation increases therapeutic effect in non-small cell lung cancer cells
by: Dyrstad, Sissel E., et al.
Published: (2022)

TARGETING THE PIK3 PATHWAY IN NON-SMALL CELL LUNG CANCER
by: DANIEL TAN SHAO WENG
Published: (2017)

REGULATION OF AMPK ACTIVATION AND ITS ROLE IN CELL DEATH INDUCED BY GLUCOSE STARVATION IN LKB1-MUTANT HUMAN LUNG CANCER CELLS
by: REN YI
Published: (2019)

Targeting microtubules sensitizes drug resistant lung cancer cells to lysosomal pathway inhibitors
by: Chin, T.-M., et al.
Published: (2021)

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
by: Tan, P.-T, et al.
Published: (2020)

Impact of smoking and brain metastasis on outcomes of advanced EGFR mutation lung adenocarcinoma patients treated with first line epidermal growth factor receptor tyrosine kinase inhibitors
by: Jain A., et al.
Published: (2020)

The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: A single South East Asian laboratory's analysis of 670 cases
by: Pang, B., et al.
Published: (2014)

CHARACTERIZING CISPLATIN-RESISTANT NSCLC CELLS AND IDENTIFYING TRAIL AS A POTENTIAL SECOND-LINE THERAPY IN REFRACTORY CANCER CELLS
by: SEAH BEE KEE SERENA
Published: (2013)

A STUDY ON STRUCTURAL, VISCOELASTIC PROPERTY AND OSTEOBLAST CHANGES IN OSTEOLYTIC METASTASES
by: CHEN XIULI
Published: (2013)

Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors
by: Eng, H.T., et al.
Published: (2014)

Impact of multidisciplinary tumour boards (MTB) on the clinicopathological characteristics and outcomes of resected colorectal liver metastases across time
by: Chen, L., et al.
Published: (2021)

Osteogenic sarcoma with skeletal muscle metastases
by: Peh, W.C.G., et al.
Published: (2016)

Molecular detection and characterization of KRAS mutations among patients with colorectal adenocarcinoma in a tertiary hospital in Metro Manila
by: Nuylan, Michelle L.
Published: (2009)

EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
by: Ma, L, et al.
Published: (2020)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
by: Lai, Gillianne GY, et al.
Published: (2024)